PATIENT
PHYSICIANS
The drug significantly improves patients’ quality of life due to the following factors:
reducing the frequency of amputations (table 1)
reducing the number of emergency admissions due to the disease progression (table 1)
increase in pain-free walking distance (up to 700% with 3 stage of disease according to Pokrovsky — Fontaine classification) (chart 1)
The following table shows a comparison the main parameters of the quality of life of patients between the group of patients receiving the drug «Neovasculgen» and the group that received only conventional treatment.
|
Indicator |
conventional treatment |
Neovasculgen |
|
Estimated number of amputations per 100 people with IIb and III stages of the disease |
10,2 |
6,3 |
|
Number of emergency hospital admissions associated with disease progression over two years of follow-up of patients who have undergone treatment |
20% |
1,7% |
|
The overall incidence of negative outcomes (death, amputation and emergency hospital admissions) for the two-year follow-up of patients who have undergone treatment |
40% |
15% |
The chart below presents data showing the dynamics of the main indicator of the effectiveness of the drug Neovasculgen — pain-free walking distance.
As can be seen from the data the highest rate in patients with initial third stage of the disease 2 years after the course of treatment
